康莱特注射液结合华蟾素片对原发性肝癌患者姑息治疗效果分析
Journal: Frontier Forum of Clinical Medicine DOI: 10.12238/ffcr.v3i6.17281
Abstract
目的：剖析原发性肝癌姑息治疗联用康莱特注射液和华蟾素片的作用。方法：随机均分2023年6月-2025年5月本院接诊原发性肝癌病人（N=70）。试验组姑息治疗期间用康莱特注射液和华蟾素片，对照组用康莱特注射液。对比NRS评分等指标。结果：关于NRS评分：治疗后，试验组（1.12±0.37）分，对照组（2.75±0.49）分，差异显著（P＜0.05）。疗效的缓解率：试验组82.86%，对照组57.14%，P＜0.05。sf-36各维度得分：治疗后，试验组高于对照组，差异显著（P＜0.05）。不良反应：试验组5.71%，对照组8.57%，P＞0.05。结论：原发性肝癌病人姑息治疗期间联用康莱特注射液和华蟾素片，其疼痛感、疗效和预后均得到较为显著的改善，用药安全性也较高。
Keywords
华蟾素片；不良反应；原发性肝癌；康莱特
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 程健珊,张弢,吴珺玮,等.华蟾素片联合肝动脉化疗栓塞术治疗原发性肝细胞癌的临床疗效及其影响因素分析[J].外科理论与实践,2024,29(4):351-357.
[2] DOMINIC SIMON, JENNIFER KALIL, MAXIMILIAN LERCHENBERGER, et al. Perioperative complications and mid-term outcomes in total hip and knee joint arthroplasty among solid organ transplant recipients: lowest reoperation-free survival and patient survivorship in lung transplant recipients[J]. Archives of Orthopaedic and Trauma Surgery,2024,145(1):151-153.
[3] 严科.康莱特注射液结合华蟾素片对原发性肝癌患者姑息治疗效果分析[J].中国全科医学,2022,14(s2):182-184.
[4] YOSHIHISA KODAMA, KAZUOMI UESHIMA, MICHIHISA MORIGUCHI, et al. Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma[J]. BMC Cancer,2024,25(1):142-144.
[2] DOMINIC SIMON, JENNIFER KALIL, MAXIMILIAN LERCHENBERGER, et al. Perioperative complications and mid-term outcomes in total hip and knee joint arthroplasty among solid organ transplant recipients: lowest reoperation-free survival and patient survivorship in lung transplant recipients[J]. Archives of Orthopaedic and Trauma Surgery,2024,145(1):151-153.
[3] 严科.康莱特注射液结合华蟾素片对原发性肝癌患者姑息治疗效果分析[J].中国全科医学,2022,14(s2):182-184.
[4] YOSHIHISA KODAMA, KAZUOMI UESHIMA, MICHIHISA MORIGUCHI, et al. Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma[J]. BMC Cancer,2024,25(1):142-144.
Copyright © 2025 袁艳虹
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License